Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Philip Tong

Dr Philip Tong

Itch Across the Ages – Practical Guide to Assessment and Management

Dr Rupert Hinds

Dr Rupert Hinds

Abdominal Pain in Children – Practical Approach in GP

Prof Roger Chen

Prof Roger Chen

Practical Guide to Improving Control of T2D

A/Prof Debbie Rigby

A/Prof Debbie Rigby

Why Inhaler Device Design and Technique Matters

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022